50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
The 3-Stock Retirement Blueprint (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
The 3-Stock Retirement Blueprint (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
The 3-Stock Retirement Blueprint (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
The 3-Stock Retirement Blueprint (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
The 3-Stock Retirement Blueprint (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
The 3-Stock Retirement Blueprint (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
The 3-Stock Retirement Blueprint (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
The 3-Stock Retirement Blueprint (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
The 3-Stock Retirement Blueprint (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
The 3-Stock Retirement Blueprint (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
The 3-Stock Retirement Blueprint (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
The 3-Stock Retirement Blueprint (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
NASDAQ:NVCR

NovoCure - NVCR Stock Forecast, Price & News

$73.63
+0.41 (+0.56%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$72.77
$75.19
50-Day Range
$67.99
$89.57
52-Week Range
$56.39
$126.66
Volume
338,767 shs
Average Volume
440,913 shs
Market Capitalization
$7.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$107.57

NovoCure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
46.1% Upside
$107.57 Price Target
Short Interest
Bearish
7.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.11mentions of NovoCure in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.86 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.89) to ($1.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

767th out of 1,069 stocks

Surgical & Medical Instruments Industry

80th out of 104 stocks

NVCR stock logo

About NovoCure (NASDAQ:NVCR) Stock

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Stock News Headlines

NovoCure (NASDAQ:NVCR) Stock Price Down 9% on Insider Selling
NovoCure Appears Poised for an Upside Breakout - RealMoney
NovoCure Appears Poised for an Upside Breakout
Why I Own Novocure Stock (NVCR)
5 Top Stocks for August - Nasdaq
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Company Calendar

Last Earnings
7/28/2022
Today
9/27/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,167
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$107.57
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+46.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-58,350,000.00
Pretax Margin
-11.37%

Debt

Sales & Book Value

Annual Sales
$535.03 million
Book Value
$3.95 per share

Miscellaneous

Free Float
98,224,000
Market Cap
$7.71 billion
Optionable
Optionable
Beta
0.79

Key Executives

  • Mr. William F. DoyleMr. William F. Doyle (Age 60)
    Exec. Chairman
    Comp: $780k
  • Mr. Asaf DanzigerMr. Asaf Danziger (Age 56)
    Pres, CEO & Director
    Comp: $1.18M
  • Ms. Ashley CordovaMs. Ashley Cordova (Age 42)
    Chief Financial Officer
    Comp: $486.45k
  • Mr. Wilhelmus C. M. GroenhuysenMr. Wilhelmus C. M. Groenhuysen (Age 64)
    Chief Operating Officer
    Comp: $639.31k
  • Mr. Pritesh ShahMr. Pritesh Shah (Age 44)
    Chief Commercial Officer
    Comp: $508.9k
  • Prof. Yoram Palti M.D. (Age 84)
    Ph.D., Founder & CTO
  • Ms. Ingrid Goldberg
    VP of Investor Relations
  • Mr. Barak Ben Arye
    Gen. Counsel
  • Mr. William Patrick Burke (Age 67)
    Chief HR Officer
  • Dr. Ely Benaim M.D. (Age 61)
    Chief Medical Officer













NVCR Stock - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVCR shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price forecast for 2022?

7 brokerages have issued 12 month target prices for NovoCure's stock. Their NVCR share price forecasts range from $55.00 to $200.00. On average, they predict the company's share price to reach $107.57 in the next year. This suggests a possible upside of 46.1% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2022?

NovoCure's stock was trading at $75.08 on January 1st, 2022. Since then, NVCR stock has decreased by 1.9% and is now trading at $73.63.
View the best growth stocks for 2022 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our NVCR earnings forecast
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, July, 28th. The medical equipment provider reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.09. The medical equipment provider had revenue of $140.90 million for the quarter, compared to analysts' expectations of $135.13 million. NovoCure had a negative trailing twelve-month return on equity of 16.04% and a negative net margin of 12.52%. The firm's revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.14) EPS.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (8.70%), Price T Rowe Associates Inc. MD (2.23%), Northern Trust Corp (0.59%), Legal & General Group Plc (0.55%), UBS Asset Management Americas Inc. (0.41%) and Swiss National Bank (0.39%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $73.63.

How much money does NovoCure make?

NovoCure (NASDAQ:NVCR) has a market capitalization of $7.71 billion and generates $535.03 million in revenue each year. The medical equipment provider earns $-58,350,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does NovoCure have?

The company employs 1,167 workers across the globe.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.

This page (NASDAQ:NVCR) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.